Abdominal aortic banding in mice induces upregulation of angiotensin II (Ang II) type 2 (AT 2 ) receptors in the pressure-overloaded thoracic aorta. To clarify mechanisms underlying the vascular AT 2 receptor-dependent NO production, we measured aortic levels of endothelial NO synthase (eNOS), eNOS phosphorylated at Ser 633 and Ser 1177 , protein kinase B (Akt), and Akt phosphorylated at Ser 473 in thoracic aortas of mice after banding. Total eNOS, both forms of phosphorylated eNOS, Akt, and phosphorylated Akt levels, as well as cGMP contents, were significantly increased 4 days after banding. The administration of PD123319 (an AT 2 receptor antagonist) or icatibant (a bradykinin B 2 receptor antagonist) abolished the banding-induced upregulation of both forms of phosphorylated eNOS, as well as elevation of cGMP, but did not affect the upregulation of eNOS, Akt, and phosphorylated Akt. In the in vitro experiments using aortic rings prepared from banded mice, Ang II produced significant increases in both forms of phosphorylated eNOS, as well as cGMP, and these effects were blocked by PD123319 and icatibant. Ang II-induced eNOS phosphorylation and cGMP elevation in aortic rings were inhibited by protein kinase A (PKA) inhibitors H89 and KT5720 but not by phosphatidylinositol 3-kinase inhibitors wortmannin and LY24002. The contractile response to Ang II was attenuated in aortic rings from banded mice via AT 2 receptor, and this attenuation was blocked by PKA inhibitors. These results suggest that the activation of AT 2 receptor by Ang II induces phosphorylation of eNOS at Ser 633 and Ser 1177 via a PKA-mediated signaling pathway, resulting in sustained activation of eNOS. (Hypertension. 2006;48:1-7.) Key Words: angiotensin II type 2 receptor Ⅲ endothelial nitric oxide synthase Ⅲ bradykinin Ⅲ signal transduction
N O is produced in the vascular system by endothelial NO synthase (eNOS). The enzymatic activity of eNOS is stimulated by a variety of mechanical forces, such as shear stress and stretching, as well as hormonal factors, including vascular endothelial growth factor, estrogen, acetylcholine, and bradykinin. [1] [2] [3] [4] [5] [6] The enzyme activity of eNOS is regulated in a Ca 2ϩ /calmodulin-dependent manner. 7 However, recent studies have demonstrated that other posttranslational modifications can regulate eNOS. 8, 9 Several phosphorylation sites on eNOS have been identified, and different protein kinases regulate phosphorylation of each site; phosphorylation of eNOS at Ser 1177 (human sequence) is mediated by protein kinase A (PKA), protein kinase B (Akt), protein kinase G, and AMP-activated protein kinase, whereas phosphorylation at Ser 633 (human sequence) is mediated by PKA. 8, 9 Phosphorylation at Ser 1177 or Ser 633 activates eNOS and increases its sensitivity to Ca 2ϩ /calmodulin, leading to enhanced NO production in endothelial cells. 8, 9 Angiotensin II (Ang II) signaling is mediated by 2 receptor subtypes, type 1 (AT 1 ) and type 2 (AT 2 ). 10 The activation of AT 1 receptors is largely responsible for the development of hypertension in Ang II-dependent hyper-tension, whereas the activation of AT 2 receptor is thought to play a counterregulatory protective role in the regulation of blood pressure that opposes the AT 1 receptor-mediated hypertensive actions of Ang II through kinin/NO-dependent mechanisms. 11 Several studies have shown that the AT 2 receptor is upregulated in cardiovascular tissues under pathological conditions, such as myocardial infarction, heart failure, hypertension, and vascular injury. 12 However, it is unknown whether increased numbers of AT 2 receptors counterbalance the AT 1 -mediated actions of Ang II under these pathological conditions.
Recently, we found that the AT 2 receptor was upregulated in thoracic aortas of rats and mice within 4 days after abdominal aortic banding 13, 14 and in mice with 2-kidney, 1-clip hypertension. 15 It was also found that aortic rings prepared from these animals exhibited an attenuated contractile response to Ang II and that this attenuation was mediated by the AT 2 receptors via the kinin/NO/cGMP cascade. 14, 15 Furthermore, the activation of AT 2 receptors in aortas of mice with 2-kidney, 1-clip hypertension resulted in eNOS phosphorylation at Ser 1177 , resulting in the enhanced production of NO. 15 These findings suggest that Ang II increases the enzyme activity of eNOS via AT 2 receptor-mediated eNOS phosphorylation, although the precise mechanisms are unknown.
Thus, the first aim of the present study was to confirm that the activation of AT 2 receptors is associated with phosphorylation of eNOS at Ser 633 and/or Ser 1177 and results in increased NO production. The second aim was to determine which protein kinases are involved in AT 2 receptor-dependent eNOS phosphorylation, because phosphorylation of eNOS at Ser 633 and Ser 1177 in intact cells by different kinases seems to be regulated by different stimuli. 8 We used thoracic aortas of mice with abdominal aortic banding, because AT 2 receptors are markedly upregulated in these aortas. Our results demonstrate that activation of AT 2 receptors induces phosphorylation of eNOS at Ser 633 and Ser 1177 in an Aktindependent and PKA-dependent manner.
Methods

Animals and Aortic Banding
All of the animal experiments were performed according to the guidelines of the Kobe Gakuin University Experimental Animal Care and Use Committee. Male, 8-week-old ICR mice (Japan SLC, Hamamatsu, Japan) weighing 35 to 37 g were used for all of the studies. Aortic banding was performed by constricting the abdominal aorta between the renal arteries just below the renal bifurcations as described previously. 16 
Western Blotting of eNOS, Phosphorylated eNOS, Akt, and Phosphorylated Akt
Protein contents of eNOS, Akt, and their phosphorylated forms in aortic tissues were measured by Western blotting, as described previously, 15 
In Vitro Experiments Using Aortic Rings
The thoracic aortas were excised 4 days after sham operation or banding and cut into 3-mm rings, as described previously. 13 Aortic rings were equilibrated for 1.5 hours in an organ bath containing a Krebs-Henseleit solution (37°C, pH 7.4) under a resting tension of 0.7 g 13 then treated with Ang II (0.1 mol/L) for 10 minutes. To examine the effects of receptor antagonists or protein kinase inhibitors, aortic rings were equilibrated in the organ bath for 1 hour, then incubated for an additional 30 minutes with PD123319 (1 mol/L; Sigma), 14 icatibant (1 mol/L; Sigma), 14, 17 wortmannin (1 mol/L; Sigma), 18 LY24002 (10 mol/L; Calbiochem), 19 H89 (10 mol/L; Cell Signaling), 18 or KT5720 (10 mol/L; Calbiochem) 19 before exposure to Ang II. Rings were frozen in dry ice acetone and kept at Ϫ80°C until they were analyzed.
Measurement of Contractile Response to Ang II in Aortic Rings
The cumulative concentration-response curves in aortic rings were constructed for Ang II (0.1 nmol/L to 1 mol/L), as described previously. 13 Receptor antagonist or kinase inhibitor was added 30 minutes before exposure to Ang II.
Assay of Aortic cGMP Content
The cGMP content in thoracic aortas or aortic rings was measured by radioimmunoassay. 13 Protein content of samples was determined by the Bio-Rad protein assay kit (Bio-Rad).
Statistical Analysis
All of the data are expressed as meanϮSE. Statistical comparison of cGMP content under various treatments was performed using 1-way ANOVA and pairwise comparisons by the Bonferroni-Dunn method.
Results
Increased eNOS and p-eNOS Contents in Thoracic Aortas of Mice After Abdominal Aortic Banding
We determined the protein content of eNOS and p-eNOS in thoracic aortas of mice 4 days after abdominal aortic banding, because the AT 2 receptor expression increases markedly in thoracic aortas of banded mice compared with sham animals. 14 The eNOS content in aortas of banded mice was Ϸ3-fold greater than those of sham animals ( Figure 1 ). Upregulation of eNOS by banding was not affected by the administration of either PD123319 (an AT 2 receptor antagonist; 10 mg/kg IP, twice a day) 20 or icatibant (a bradykinin B 2 receptor antagonist; 0.5 mg/kg IP, once a day) 21 for 4 days after banding ( Figure 1 ). As shown in Figure 1 , aortic contents of p-eNOS at Ser 633 and at Ser 1177 in banded mice were Ϸ3-fold greater than in sham animals, and these upregulations of p-eNOS were completely inhibited by administration of PD123319 or icatibant for 4 days. Neither PD123319 nor icatibant affected the levels of eNOS and p-eNOS in sham animals (data not shown). 
Increased Akt and p-Akt Contents in Thoracic Aortas of Mice After Abdominal Aortic Banding
Akt, a serine/threonine kinase that is a major target of phosphatidylinositol 3-kiniase (PI3K), phosphorylates eNOS at Ser 1177 , and this phosphorylation enhances eNOS activity and increases NO production in vascular endothelial cells. 22, 23 Protein levels of both Akt and p-Akt at Ser 473 in thoracic aortas were significantly increased in aortas of banded mice compared with sham mice (Figure 2 ). The administration of PD123319 or icatibant for 4 days after banding did not affect the banding-induced upregulation of Akt and p-Akt ( Figure  2 ). PD123319 and icatibant did not affect the aortic content of Akt and p-Akt in sham animals (data not shown).
Increased cGMP Content in Thoracic Aortas of Mice After Abdominal Aortic Banding
The cGMP contents in thoracic aortas of banded mice were 6-fold greater than those in sham mice (18.13Ϯ1.87 fmol/mg of protein in 6 banded mice versus 3.05Ϯ0.48 fmol/mg of protein in 6 sham-mice; PϽ0.001; Figure 3 ). The bandinginduced elevation of aortic cGMP was abolished by administration of PD123319 or icatibant for 4 days after banding (Figure 3 ). PD123319 and icatibant did not affect the aortic cGMP content in sham animals (data not shown).
Effects of Ang II on eNOS and p-eNOS Levels in Aortic Rings In Vitro
To determine the involvement of Ang II in eNOS phosphorylation, we studied the in vitro effects of Ang II on levels of eNOS and p-eNOS in aortic rings prepared from sham and banded mice. The basal levels of eNOS, p-eNOS-Ser 633 , and p-eNOS-Ser 1177 were significantly greater in aortic rings from banded mice than those from sham mice, although aortic rings were incubated in vitro for 1.5 hours after the excision (Figure 4 ). Basal levels of these proteins in aortic rings from banded mice were not affected by an in vitro treatment with PD123319 (1 mol/L) or icatibant (1 mol/L) for 30 minutes (data not shown). Treatment with Ang II (0.1 mol/L) for 10 minutes did not affect the contents of eNOS in aortic rings from banded mice ( Figure 4 ) or sham mice (data not shown). In contrast, the levels of both p-eNOS-Ser 633 and p-eNOS-Ser 1177 were further increased in aortic rings from banded mice after treatment with Ang II (Figure 4 ), whereas aortic rings from sham mice were not affected by Ang II (data not shown). The elevation of p-eNOS-Ser 1177 or p-eNOS-Ser 633 by Ang II was significantly inhibited by PD123319 (1 mol/L) or icatibant (1 mol/L; Figure 4 ).
Effects of Ang II on Akt and p-Akt Levels in Aortic Rings In Vitro
The basal levels of Akt and p-Akt at Ser 473 were significantly greater in aortic rings from banded mice than those from sham mice (data not shown). Treatment with Ang II (0.1 mol/L) for 10 minutes did not affect the contents of Akt and p-Akt in aortic rings from banded mice (data not shown).
Effects of Protein Kinase Inhibitors on Ang II-Induced Phosphorylation of eNOS in Aortic Rings
To determine which protein kinases are involved in AT 2 receptor-mediated phosphorylation of eNOS, aortic rings pretreated with PI3K inhibitors (wortmannin, 1 mol/L; LY24002, 10 mol/L) or PKA inhibitors (H89, 10 mol/L; KT5720, 10 mol/L) were exposed to Ang II for 10 minutes. Neither wortmannin nor LY24002 affected the Ang IIinduced increases of p-eNOS-Ser 1177 and p-eNOS-Ser 633 in aortic rings from banded mice ( Figure 5 ). In contrast, pretreatment of aortic rings from banded mice with H89 or KT5720 resulted in a significant inhibition of Ang II-induced increases in both p-eNOS-Ser 633 and p-eNOS-Ser 1177 ( Figure  5 ). These PKA inhibitors did not affect the basal levels of p-eNOS-Ser 1177 and p-eNOS-Ser 633 (data not shown). These protein kinase inhibitors did not affect the levels of total eNOS ( Figure 5) , Akt, and p-Akt (data not shown) in Ang II-treated or untreated aortic rings from banded mice.
Effects of AT 2 and B 2 Receptor Antagonists and Protein Kinase Inhibitors on Ang II-Induced Increases in cGMP Contents of Aortic Rings
The cGMP content of aortic rings from banded mice was significantly greater than in aortic rings from sham mice (10.05Ϯ1.12 fmol/mg of protein in 8 banding rings versus 2.33Ϯ0.32 fmol/mg of protein in 8 sham-rings; PϽ0.001; Figure 6 ). Basal levels of cGMP in rings from banded mice were not affected by an in vitro treatment with PD123319 (1 mol/L), icatibant (1 mol/L), wortmannin (1 mol/L), LY24002 (10 mol/L), H89 (10 mol/L), or KT5720 (10 mol/L) for 30 minutes (data not shown).
Treatment with Ang II (0.1 mol/L) for 10 minutes resulted in a significant elevation of cGMP contents in aortic rings from banded mice compared with basal levels (30.11Ϯ1.55 fmol/mg of protein in 8 Ang II-treated rings versus 10.05Ϯ1.12 fmol/mg of protein in 8 untreated rings; PϽ0.001; Figure 6 ). Either PD123319 (1 mol/L) or icatibant (1 mol/L) almost completely inhibited the Ang II-induced increases in cGMP contents ( Figure 6 ). The Ang II-induced increases in cGMP were not affected by wortmannin (1 mol/L) and LY24002 (10 mol/L) but were strongly inhibited by H89 (10 mol/L; 18.02Ϯ1.31 fmol/mg of protein in 8 rings) and KT5720 (10 mol/L; 17.95Ϯ1.41 fmol/mg of protein in 8 rings) versus Ang II alone (30.11Ϯ1.55 fmol/mg of protein in 8 rings; PϽ0.001; Figure 6 ).
Effects of Protein Kinase Inhibitors on the AT 2 Receptor-Mediated Attenuation of Ang II-Induced Contractile Response of Aortic Rings
Ang II-induced contractile response was attenuated in aortic rings from banded mice as compared with those from sham mice, and this attenuation was inhibited by either PD123319 or icatibant ( Figure 7A ). Pretreatment with PKA inhibitors (H89, 10 mol/L; KT5720, 10 mol/L; Figure 7C ) but not PI3K inhibitors (wortmannin, 1 mol/L; LY24002, 10 mol/L; Figure 7B ) also significantly inhibited the attenuation of Ang II-induced contractile response in aortic rings from banded mice. These protein kinase inhibitors did not affect the Ang II-induced contractile response in aortic rings from sham mice (data not shown).
Discussion
As demonstrated in previous studies using the mouse and rat, 13, 14 abdominal aortic banding induces upregulation of AT 2 receptors in the thoracic aorta, and the activation of aortic AT 2 receptors in banded mice by Ang II results in enhanced NO production and increased cGMP. 14 The upregulated AT 2 receptors may be continuously stimulated by Ang II in banded animals, because the circulating levels of Ang II are elevated after banding, 24 and the administration of PD123319 abolished the elevation of cGMP in thoracic aortas of animals with banding. 14 Thus, it is likely that the AT 2 Figure 6 . In vitro effects of receptor antagonists and protein kinase inhibitors on Ang II-induced elevation of cGMP in aortic rings. Aortic rings were prepared from mice 4 days after sham operation or banding. After equilibration for 1 hour in an organ bath, aortic rings were incubated for 30 minutes with or without PD123319 (PD; 1 mol/L), icatibant (Icat; 1 mol/L), wortmannin (Wort; 1 mol/L), LY24002 (LY; 10 mol/L), H89 (10 mol/L), or KT5720 (KT; 10 mol/L) then treated with Ang II (0.1 mol/L) for 10 minutes. Values are the meanϮSEM (nϭ8). *PϽ0.001 vs sham-rings; #PϽ0.001 vs untreated banded rings; §PϽ0.001 vs Ang II-treated banded rings. receptor functionally couples to the activation of the NO/ cGMP system.
The phosphorylation of eNOS at Ser 633 or Ser 1177 results in reduced calcium dependence and sustained release of endothelial NO. 8, 9 The eNOS is phosphorylated at Ser 1177 by Akt, which is phosphorylated and activated by PI3K. 22, 23 In the present studies, we found that abdominal aortic banding resulted in increased levels of eNOS, p-eNOS at Ser 633 and Ser 1177 , Akt, and p-Akt at Ser 473 in the thoracic aortas. The administration of PD123319 completely inhibited the banding-induced increases in p-eNOS, suggesting a mediation of AT 2 receptors in eNOS phosphorylation. Like PD123319, the administration of icatibant abolished the banding-induced elevation of both p-eNOS and cGMP in aortas, confirming previous studies that the AT 2 receptormediated vasodilator response to Ang II is mediated by a kinin/NO-dependent mechanism. 14, 15 In contrast, the bandinginduced increases in total eNOS, total Akt, and p-Akt were not affected by PD123319 or icatibant, suggesting that upregulation of these proteins is independent of AT 2 and B 2 receptors and, hence, is not associated with increased production of NO in thoracic aortas of banded mice. The mechanisms underlying the banding-induced upregulation of these proteins are unknown, but changes in the mechanical forces on the vascular wall may be important. [1] [2] [3] To confirm further that the activation of AT 2 receptors by Ang II is associated with eNOS phosphorylation, aortic rings were prepared from banded mice and treated with Ang II in vitro. Ang II produced increased levels of p-eNOS-Ser 633 and p-eNOS-Ser 1177 , as well as cGMP. These effects of Ang II on both p-eNOS and cGMP levels were blocked by PD123319 or icatibant, suggesting that Ang II stimulates NO production through activation of eNOS by phosphorylation at Ser 633 and/or at Ser 1177 via the AT 2 and B 2 receptors. In contrast, p-Akt levels in aortic rings from banded mice were not affected by Ang II, suggesting that Akt is not a downstream effector of the AT 2 receptor in eNOS phosphorylation.
The cGMP levels remained elevated in aortic rings from banded mice compared with sham rings, although the aortic rings were incubated without addition of Ang II for 1.5 hours after excision, suggesting that NO production remained elevated during the in vitro experiments. Because treatment with PD123319 did not affect the basal levels of cGMP in aortic rings from banded mice, it is unlikely that Ang II generated in aortic rings is responsible for the sustained NO production. Rather, it seems likely that the activation of eNOS before excision of aortas was maintained for Ն1.5 hours in vitro. This is similar to data showing that both p-eNOS-Ser 633 and p-eNOS-Ser 1177 after treatment with shear stress or 8-bromo-cAMP remain at elevated levels in bovine endothelial cells for Յ1 hour. 25 In this study, we found that the Ang II-induced elevations of p-eNOS-Ser 633 and p-eNOS-Ser 1177 , as well as cGMP contents in aortic rings from banded mice, were inhibited by PKA inhibitors but not by PI3K inhibitors. PKA inhibitors also exhibited a significant inhibition on the AT 2 receptordependent attenuation of Ang II-induced contractile response in aortic rings from banded mice. These results suggest that the AT 2 receptor-dependent eNOS phosphorylation at Ser 633 or Ser 1177 , as well as vasodilator response to Ang II, is mediated by PKA.
The stimulation of AT 2 receptors causes local production of bradykinin in vessels and myocardium, which, in turn, stimulates B 2 receptors to activate the NO/cGMP cascade. 26, 27 Our present study also supports B 2 receptor-mediated cGMP production in aortas of banded mice, suggesting that bradykinin is an important mediator involving in the AT 2 receptor-dependent phosphorylation of eNOS. Bradykinin can induce PKAdependent eNOS phosphorylation at Ser 633 and Akt-dependent phosphorylation at Ser 1177 . 9 However, a recent study using bovine endothelial cells demonstrated that bradykinin-induced eNOS phosphorylation at Ser 1177 , as well as NO production, was blocked by a PKA inhibitor but not by a PI3K inhibitor. 28 Our present results are consistent with these studies indicating that bradykinin stimulates eNOS phosphorylation at Ser 633 and Ser 1177 via PKA-dependent mechanisms. These data further support a potential role of bradykinin as a downstream effector of the AT 2 receptor.
Perspectives
The present study demonstrates that the vascular AT 2 receptor mediates the vasodilator action of Ang II through PKAdependent phosphorylation of eNOS, which results in enhanced NO production in endothelial cells. Bradykinin is probably an important mediator involved in eNOS phosphorylation in a signaling pathway downstream of AT 2 receptor. These data will help our understanding of the vasoprotective actions of AT 1 receptor antagonists in cardiovascular diseases, in which the vascular AT 2 receptor is upregulated.
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